Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
Disorders of Leukocytes01:27

Disorders of Leukocytes

935
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
935

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities.

Bone marrow transplantation·2026
Same author

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.

Bone marrow transplantation·2026
Same author

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same author

T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Bone marrow transplantation·2026
Same author

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Jun 22, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Multiple myeloma.

Florent Malard1, Paola Neri2, Nizar J Bahlis2

  • 1Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France. florent.malard@inserm.fr.

Nature Reviews. Disease Primers
|June 27, 2024
PubMed
Summary

Multiple myeloma (MM) is a complex blood cancer affecting plasma cells, often relapsing after treatment. Current therapies include stem cell transplants for younger patients and novel immunotherapies for relapsed or older individuals.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

Related Experiment Videos

Last Updated: Jun 22, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma (MM) is the second most common hematological malignancy, characterized by plasma cell proliferation and monoclonal immunoglobulin production.
  • Despite increasing incidence, MM remains incurable due to frequent relapse and treatment refractoriness.
  • MM is a genetically complex and heterogeneous disease involving tumor cell alterations and bone marrow microenvironment changes.

Purpose of the Study:

  • To provide an overview of multiple myeloma (MM), including its diagnosis, current treatment strategies, and emerging therapies.
  • To highlight the challenges in MM treatment, such as disease heterogeneity and relapse.
  • To discuss the evolving landscape of MM management, incorporating novel immunotherapies.

Main Methods:

  • Diagnosis relies on International Myeloma Working Group criteria, including bone marrow infiltration and myeloma-defining events (CRAB features or biomarkers).
  • Treatment approaches are stratified by patient age and fitness, with autologous hematopoietic cell transplantation for eligible individuals.
  • For transplant-ineligible older adults, combination therapy (daratumumab, lenalidomide, dexamethasone) is preferred.

Main Results:

  • Treatment protocols involve induction, consolidation (high-dose melphalan and autologous stem cell transplant), and maintenance therapy for eligible patients.
  • Relapsed or refractory MM cases are managed based on prior treatments, with increasing use of immunotherapies.
  • Emerging immunotherapies include bi-specific monoclonal antibodies and chimeric antigen receptor T cell therapy.

Conclusions:

  • Multiple myeloma remains a significant clinical challenge due to its complexity and resistance to treatment.
  • Treatment strategies are advancing, offering improved outcomes for both transplant-eligible and ineligible patients.
  • The integration of novel immunotherapies represents a promising frontier in managing relapsed and refractory multiple myeloma.